EBErica Bäckström

Erica Bäckström

*This is an algorithmically generated author record based on publicly available information.

Erica Bäckström has a total of 20 co-authors. Here are the top co-authors by number of shared publications:

  • Markus Fridén

    Drug Metabolism and Pharmacokinetics, Research and Early Development, Respiratory, Inflammation and Autoimmune (RIA), BioPharmaceuticals R&D, AstraZeneca, Mölndal, Sweden

    3 shared publications
  • Britt-Marie Fihn

    Drug Metabolism and Pharmacokinetics, Research and Early Development, Respiratory, Inflammation and Autoimmune (RIA), BioPharmaceuticals R&D, AstraZeneca, Mölndal, Sweden

    2 shared publications
  • Anders Lundqvist

    Respiratory, Inflammation and Autoimmunity Innovative Medicines, AstraZeneca R&D Gothenburg, Mölndal 431 83, Sweden

    1 shared publication
  • Anna Abrahamsson

    Drug Metabolism and Pharmacokinetics, Research and Early Development, Respiratory, Inflammation and Autoimmune (RIA), BioPharmaceuticals R&D, AstraZeneca, 431 83 Gothenburg, Sweden

    1 shared publication
  • Anna Nilsson

    C Biomolecular Mass Spectrometry Imaging, National Resource for MSI, Science for Life Laboratory, Dept. of Pharmaceutical Biosciences , Uppsala University , Uppsala , Sweden

    1 shared publication
  • Britta Bonn

    Drug Metabolism and Pharmacokinetics, Research and Early Development, Respiratory, Inflammation and Autoimmune (RIA), BioPharmaceuticals R&D, AstraZeneca, 431 83 Gothenburg, Sweden

    1 shared publication

Latest Publications

  • Broncho-alveolar lavage procedure extract compounds from surrounding tissue

    by Erica Bäckström, Britt-Marie Fihn, Teodor Erngren, Walter Lindberg, Lina Odqvist, Markus Fridén, Ken Grime

    Broncho-alveolar lavage (BAL) is routinely used for collection of cells from the alveolar space and for sampling of epithelial lining fluid (ELF) in lungs in preclinical studies. Urea is present in all tissue at the same concentration and therefore is commonly used as a dilution marker of the BAL fluid to calculate back to compound concentration in ELF. The aim of the present study was to investigate the accuracy of ELF concentration determination and the possible extraction from surrounding tissue of compounds with diverse physicochemical properties, using different BAL volumes and repeated BAL procedure. Propranolol, diazepam, indomethacin, AZD4721, and anakinra were delivered as an intravenous (IV) bolus dose followed by an IV infusion for 4 h to reach steady state. BAL was performed with 1 mL, 4 mL, or repeatedly with 4 mL and samples from BAL, plasma and lung tissue were taken for bioanalysis. Repeated BAL procedure revealed significant extraction from tissue as the concentration in sequential BAL fluid samples decreased slowly: >60% of the concentration of propranolol in the first BAL fluid sample was still present in the fifth sample of BAL fluid. BAL procedure with 4 mL resulted in more extraction of urea as well as compounds from tissue and/or blood compared to BAL procedure with 1 mL. Small molecules (propranolol, diazepam, indomethacin, AZD4721) were extracted from tissue to a higher degree than the large protein drug anakinra. The present study clearly demonstrates that BAL procedure results in extraction of urea and compounds from surrounding tissue and the procedure is therefore not fit for the purpose of determination of compound concentrations in ELF.

  • Open Access

    Pulmonary Metabolism of Substrates for Key Drug-Metabolizing Enzymes by Human Alveolar Type II Cells, Human and Rat Lung Microsomes, and the Isolated Perfused Rat Lung Model

    by Katarina Rubin, Pär Ewing, Erica Bäckström, Anna Abrahamsson, Britta Bonn, Satoshi Kamata, Ken Grime

    Significant pulmonary metabolism of inhaled drugs could have drug safety implications or influence pharmacological effectiveness. To study this in vitro, lung microsomes or S9 are often employed. Here, we have determined if rat and human lung microsomes are fit for purpose or whether it is better to use specific cells where drug-metabolizing enzymes are concentrated, such as alveolar type II (ATII) cells. Activities for major hepatic and pulmonary human drug-metabolizing enzymes are assessed and the data contextualized towards an in vivo setting using an ex vivo isolated perfused rat lung model. Very low rates of metabolism are observed in incubations with human ATII cells when compared to isolated hepatocytes and fewer of the substrates are found to be metabolized when compared to human lung microsomal incubations. Reactions selective for flavin-containing monooxygenases (FMOs), CYP1B1, CYP2C9, CYP2J2, and CYP3A4 all show significant rates in human lung microsomal incubations, but all activities are higher when rat lung microsomes are used. The work also demonstrates that a lung microsomal intrinsic clearance value towards the lower limit of detection for this parameter (3 µL/min/mg protein) results in a very low level of pulmonary metabolic clearance during the absorption period, for a drug dosed into the lung in vivo.


  • Open Access

    Uncovering the regional localization of inhaled salmeterol retention in the lung

    by Erica Bäckström, Gregory Hamm, Anna Nilsson, Britt-Marie Fihn, Nicole Strittmatter, Per Andrén, Richard J. A. Goodwin, Markus Fridén

    Treatment of respiratory disease with a drug delivered via inhalation is generally held as being beneficial as it provides direct access to the lung target site with a minimum systemic exposure. There is however only limited information of the regional localization of drug retention following inhalation. The aim of this study was to investigate the regional and histological localization of salmeterol retention in the lungs after inhalation and to compare it to systemic administration. Lung distribution of salmeterol delivered to rats via nebulization or intravenous (IV) injection was analyzed with high-resolution mass spectrometry imaging (MSI). Salmeterol was widely distributed in the entire section at 5 min after inhalation, by 15 min it was preferentially retained in bronchial tissue. Via a novel dual-isotope study, where salmeterol was delivered via inhalation and d3-salmeterol via IV to the same rat, could the effective gain in drug concentration associated with inhaled delivery relative to IV, expressed as a site-specific lung targeting factor, was 5-, 31-, and 45-fold for the alveolar region, bronchial sub-epithelium and epithelium, respectively. We anticipate that this MSI-based framework for quantifying regional and histological lung targeting by inhalation will accelerate discovery and development of local and more precise treatments of respiratory disease.


  • Lung Retention by Lysosomal Trapping of Inhaled Drugs Can Be Predicted In Vitro With Lung Slices

    by Erica Bäckström, Elin Boger, Anders Lundqvist, Margareta Hammarlund-Udenaes, Markus Fridén